

Isolation of Heavy Chain Class Switch Variants of a Monoclonal Anti-DC1 Hybridoma Cell Line: Effective Conversion of Noncytotoxic IgG₁ Antibodies to Cytotoxic IgG₂ Antibodies

Peter Parham, Thomas J. Kipps, Frances E. Ward, and Leonard A. Herzenberg

ABSTRACT: *Spontaneously arising class switch variants of the Genox 3.53 hybridoma cell line were isolated. They secrete IgG_{2a} or IgG_{2b} monoclonal antibodies of anti-DC1 specificity identical to that of the IgG₁ secreting parental cell. In contrast to the parental monoclonal antibody, those secreted by the variants are cytotoxic to peripheral blood B lymphocytes of DC1 positive individuals and are thus compatible with existing HLA typing techniques. This provides a general method for converting noncytotoxic anti-HLA antibodies into cytotoxic typing reagents.*

ABBREVIATIONS

PBS	phosphate buffered saline pH 7.4	SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
FACS	fluorescence activated cell sorter	FITC	fluorescein isothiocyanate
GAM1	goat anti-mouse IgG ₁	PI	propidium iodide
GAM2	goat anti-mouse IgG ₂		
RAM	F(ab') ₂ rabbit anti-mouse IgG		

INTRODUCTION

Monoclonal antibodies are potentially useful reagents for HLA typing. In order to be compatible with existing typing methods they must mediate complement dependent cytotoxicity. Mouse immunoglobulins of the IgG_{2a} or the IgG_{2b} isotype do fix complement, and monoclonal anti-HLA antibodies of these classes are generally cytotoxic to human peripheral blood lymphocytes of the appropriate HLA type. However, many mouse monoclonal antibodies are of the IgG₁ isotype, an immunoglobulin class unable to fix complement. One way of making such

From the Department of Genetics and the Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305; and the Division of Immunology, Duke University Medical Center, Durham, NC 27710.

Address requests for reprints to Peter Parham, Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305.

Received March 21, 1983; accepted April 29, 1983.

antibodies cytotoxic is to use them in conjunction with a complement fixing anti-immunoglobulin reagent [1,2]. Another approach is to isolate spontaneous variants of hybridoma cells that secrete an immunoglobulin of different antibody heavy chain isotype [3] but have the same variable region and combining site specificity as the original antibody. Such "switch variant" hybridomas are obtained by staining a large number of parent hybridoma cells with fluorescent antibodies specific for the variant heavy chain isotype and then selecting for fluorescent cells with the fluorescence activated cell sorter (FACS). In this manner families of hybridomas have been generated, each producing immunoglobulins with identical combining sites but with different heavy chain constant regions [4,5].

Application of such switch variant technology may thus be useful for generating monoclonal antibodies for HLA typing from the noncytotoxic anti-HLA antibody producing hybridomas that have been characterized. Here we describe the successful application of this approach to the Genox 3.53 producing hybridoma cell line [6]. The Genox 3.53 antibody recognizes the polymorphic specificity DC1 associated with products of the second series of human class II MHC antigens. The DC1 antigenic specificity is alternatively called MB1 or MT1 by different laboratories. The DC1 antigen is often found on cells expressing the antigens DR-1,2, w6, and w10 of the first series of human class II MHC antigens. For this reason, it was initially thought that Genox 3.53 recognized a supertypic specificity of DR antigen [6]. However, structural characterization of the molecules recognized by this antibody have shown they are different from DR and have amino acid sequence homology with mouse I-A chains [7,8]. This antibody has been useful in establishing the existence and identity of the second series of human Ia-like antigens [7]. The availability of IgG₂ variants increases its utility both as a cytotoxic HLA typing reagent and as immunochemical tool. IgG₂ binds more strongly to Staphylococcus protein A than IgG₁ and thus the switch variants are more easily used in standard immunoprecipitation procedures and may be readily purified on columns of protein A.

MATERIALS AND METHODS

Preparation of goat anti-mouse IgG₁ and IgG₂. Individual goats were immunized with IgG₁, IgG_{2a}, and IgG_{2b} myeloma proteins: 50 ml of anti-IgG₁ serum and a pool of anti-IgG_{2a} (50 ml) plus anti-IgG_{2b} (150 ml) serum were used as starting materials. The antisera were clarified by centrifugation at 100,000 g for 1 hr and the supernatant made 50% saturated in ammonium sulphate. After centrifugation at 6000 g for 30 min the supernatant was discarded and the pellet resuspended in 100 ml of PBS. These preparations were then applied to various affinity columns. Twenty ml affinity columns of myeloma proteins coupled to cyanogen bromide activated Sepharose 4B were used. Activation of Sepharose and coupling with purified IgG at a concentration of 10 mg/ml were by the method of March et al. [9]. The efficiency of coupling was \approx 50%.

Anti-IgG₂ (GAM2). The sample was applied to a column of IgG₁ Sepharose with a 1 ml precolumn of Sephadex G50 and washed through with PBS. The flow-through was saved, the G50 column discarded, and the IgG₁ column eluted with 50 ml of 50 mM diethylamine-HCl, pH 12.0 [10]. The eluted material was neutralized and frozen, the column was re-equilibrated with PBS. This procedure was repeated seven times with the flow-through fraction taken as sample for the next cycle. In this way the anti-IgG₂ serum was depleted of anti-IgG₁ cross-reactivity. In a similar fashion, anti-IgM cross-reactivity was depleted by two cycles over an IgM column. The next step was to apply the sample to a G50

precolumn followed by a mixed IgG_{2a}, IgG_{2b} column. The sample was washed through with PBS and the column then washed with 100 ml PBS, 50 ml PBS + 0.5 M NaCl, and 100 ml PBS. After elution with 50 mM diethylamine-HCl pH 12.0 the previously bound material was neutralized with 0.5 M tris-HCl pH 7.5 and dialyzed against PBS. The dialyzed material was centrifuged at 6,000 g for 30 min and the supernatant passed through an IgG₁ column to remove any residual cross-reactive material. The flow-through was concentrated to 1 mg/ml by ultrafiltration. The flow-through from the IgG₂ column was recycled three times over the IgG₂ columns to ensure complete removal of all anti-IgG₂ antibodies. The material eluted with pH 12.0 buffer was further processed as described above. Only the first two eluates gave significant amounts of protein. Sixteen mg of anti-IgG₂ was thus obtained.

Anti-IgG₁ (GAM1). The procedure was as for anti-IgG₂ except that the sample was depleted on IgG₂ and IgM columns and then positively selected for an IgG₁ column. Thirty-four mg of anti-IgG₁ was obtained.

Specificity of GAM1 and GAM2. The GAM1 and GAM2 were >90% IgG as assessed by SDS-PAGE. Fifty μ g aliquots were iodinated and tested for binding to monoclonal antibodies of different isotypes in solid phase and cell binding assays. As shown in Figure 1 the cross-reactions of the anti-IgG₁ onto IgG₂ and of anti-IgG₂ onto IgG₁ were weak. Anti-IgG₂ reacted 2–3 times more strongly with IgG_{2b} than with IgG_{2a}. About 40% of the radioactivity in each preparation bound to IgG of the appropriate isotype.

Fluorescence conjugation. GAM1 and GAM2 were conjugated to fluorescein isothiocyanate (FITC) by a modification of the method of Goding [11]. The purified goat antibody preparation was applied to a Sephadex G-25 column equilibrated with 0.5 M carbonate buffer pH 9.5. Antibody fractions found in the excluded volume were pooled prior to reacting with FITC. Because of the relatively low antibody concentrations (0.6–1 mg/ml), FITC dissolved in dimethylsulfoxide (10 mg/ml) was added in excess at 140 μ g FITC per milligram of protein. The reaction was allowed to proceed for 4 hr at room temperature with end-over-end shaking. The reaction was terminated by passing the mixture over a Sephadex G-25 column equilibrated with phosphate buffered saline at pH 7.4 (PBS). Antibody fractions in the excluded volume were again collected. Fluorochrome-protein conjugates




FIGURE 1 Specificity of ¹²⁵I-GAM1 and ¹²⁵I-GAM2 in solid phase radioimmuno assay. Monoclonal antibodies of different isotype were adsorbed to wells of microtitre plates and then incubated with 3×10^5 cpm ($\approx 10^7$ cpm/ μ g) of ¹²⁵I-GAM1 or ¹²⁵I-GAM2 for 1 hr at 4°C. The plates were washed, the wells separated and assayed for bound radioactivity. W6/32 was derived from a fusion with an IgG₁ secreting myeloma cell line and the antibody preparation contains nonspecific IgG₁ heavy chain and κ light chain in addition to the W6/32 chains [25].

were analyzed spectrophotometrically at 280 and 493 nm and the fluorescence to protein conjugation ratios calculated using the formula and nomogram given in Goldman [12]. The fluorescence to protein ratios were ~ 2.8 for the FITC-GAM1 and ~ 3.4 for the FITC-GAM2 preparations. These reagents were titrated against mouse hybridoma cells of known isotype and analyzed for cell surface staining with a fluorescent activated cell sorter (FACS) (FACS II Becton Dickinson, Mountain View, CA).

Cell lines and culture conditions. The production of the Genox 3.53 cell line has been described [6]. It secretes an IgG₁ antibody with specificity for the DC1 allelic product of the second series of human class II MHC antigens. This specificity is alternatively known as MB1 and MT1. Monoclonal antibodies MRC OX3 [13] and BT3/4 [14] are of similar specificity. The hybridomas 190-59.2 and 197-24.63 used to test the isotype specificity of FITC-GAM1 and FITC-GAM2 secreted either IgG₁ or IgG₂ antibodies with specificity for the hapten dansyl (5-[dimethylamino]naphthalene-1-sulfonyl).

Hybridoma cells were cultured in RPM1-1640 medium (GIBCO) supplemented with 2 mM L-Glutamine, 1 mM sodium pyruvate, and 15% horse serum or 10% fetal calf serum at 37° in a 7% CO₂-in-air incubator. The medium for Genox 3.53 cells was also supplemented with 0.1 mM hypoxanthine and 1.6×10^{-2} mM thymidine. Elimination of these components resulted in slower cell growth, reduced viability, and poor cloning efficiency for this cell line.

Human B lymphoblastoid cells used as targets for indirect binding assays were LB which is DR6 and positive for DC1 and Mich which is DR5 and negative for DC1. The cell lines were grown in RPM1 1640 supplemented with 2 mM L-Glutamine and 10% fetal calf serum.

Radioimmune assays. Indirect cell binding assays were as described [15]. For solid phase radioimmune assays 25 μ l of purified immunoglobulins (0–25 μ g) on PBS were added to the wells of flexible microtitre plates and incubated on ice for 1 hr. The antibody was removed, the wells filled with 0.2% BSA in PBS, and incubated on ice for 1 hr. Radioiodinated GAM1, GAM2, or RAM (300,000 cpm in 25 μ l) was added and incubated on ice for 1 hr. The plates were washed four times with 0.2% BSA in PBS and the wells separated with a hot wire cutting device and assayed for bound radioactivity. In experiments to distinguish IgG_{2a} from IgG_{2b} variants the monoclonal anti-mouse IgG allotype antibodies 8.3 (anti-Igh-1a) and 16.3 (anti-Igh-1a,3a) were used [16]. 8.3 has specificity for IgG_{2a} and 16.3 has specificity for both IgG_{2a} and IgG_{2b} of C3H mice from which Genox 3.53 was derived [6].

Fluorescent staining of cells. Cultured cells to be analyzed or sorted were centrifuged ($200 \times g$ for 4 min) and washed twice with staining media (RPM1 1640 medium supplemented with 10 mM HEPES and then adjusted to pH 7.5 with 5 M HCl) at 4°C. After resuspension in staining medium the cell concentration and viability were determined by staining an aliquot with a one part per million solution of acridine orange with ethidium bromide and counting the viable and dead cells in a hemacytometer. Viable cells comprised >95% of all cell suspensions that were analyzed or sorted. Cells to be stained were transferred to 12 \times 75 plastic tubes (Falcon) and centrifuged at $200 \times g$ for 4 min. Supernates were decanted and the cells resuspended in staining medium containing FITC-GAM1 or FITC-GAM2 and 0.3 μ g/ml of propidium iodide (PI). FITC-GAM1 and FITC-GAM2 were titrated against a panel of monoclonal antibody producing hybridomas of different immunoglobulin isotypes at different concentrations and amounts

of antibody for a fixed number of hybridoma cells. Representative titrations of FITC-GAM2 are presented in Table 1. As can be seen both the concentration of the staining reagent as well as the absolute amount of antibody were important in determining the mean fluorescence of the stained cell populations. Similar results with FITC-GAM1 were also obtained. A concentration of 50 $\mu\text{g/ml}$ of goat antibody for either isotype was chosen for subsequent stainings. Volumes were such that there was 1–1.5 μg of antibody per 10^6 cells. When staining to select for rare variant cells, FITC-GAM2 was used at 0.3 μg per 10^6 cells. Control cell samples were incubated with staining medium containing 0.3 $\mu\text{g/ml}$ PI. Staining was for 20 min at 4°C. The cells were washed twice by centrifugation with

TABLE 1 Binding of FITC-GAM2 to Hybridoma Cells Secreting Anti-Dansyl IgG of Different Isotype

Hybrid cell line	Isotype	Antibody concentration ($\mu\text{g/ml}$)	Amount of antibody ($\mu\text{g}/10^6$ cells)	Mean fluorescence (arbitrary units)
190-59.2	IgG _{2a}	80	10	116
			3	113
			1	108
			0.3	95
		40	10	114
			3	112
			1	107
			0.3	92
		8	10	97
			3	96
			1	86
			0.3	75
			0.1	74
	No stain	—	57	
197-24.63	IgG ₁	80	10	67
			3	64
			1	61
			0.3	61
		40	10	66
			3	62
			1	61
			0.3	60
		8	10	62
			3	60
			1	61
			0.3	60
			0.1	59
	No stain	—	59	

excess cold staining medium and resuspended at $\approx 10^6/\text{ml}$ for FACS analysis and sorting.


Culture and cloning of switch variant hybridoma cells. During the initial rounds of variant selection, sorted Genox 3.53 cells were collected into a single well of a 24 well culture plate (Costar), containing culture medium. After sorting 10^7 BALB/c thymocytes were added to this well to provide a feeder cell layer. Thymocyte suspensions were prepared as described [17] and washed three times with medium. For cell cloning, an electronic modification of the FACS was used to sort single cells into individual wells of a 96-well culture plate (Falcon) containing $50 \mu\text{l}$ of medium [18]. After cloning, $50 \mu\text{l}$ of medium containing 10^6 washed thymocytes was added to each well.

RESULTS AND DISCUSSION

FITC-GAM1 and FITC-GAM2 were titrated against a panel of mouse hybridomas of known immunoglobulin isotype. Cell surface staining was analyzed with the FACS. FITC-GAM2 specifically stained IgG_{2a} or IgG_{2b} producing hybridoma cells with amounts of $1.5 \mu\text{g}/10^6$ cells at a concentration of $50 \mu\text{g}/\text{ml}$ (Table 1). No specific staining of hybridomas producing immunoglobulin of other isotypes was observed. Similarly FITC-GAM1 specifically stained IgG_1 producing hybridomas with amounts of $1.0 \mu\text{g}/10^6$ cells at a concentration of $50 \mu\text{g}/\text{ml}$.

Genox 3.53 hybridoma cells stained specifically with FITC-GAM1 and not with FITC-GAM2 as shown in Figure 2(A). This was to be expected as it was known that the cells secreted an IgG_1 . Careful analysis of the population stained

FIGURE 2 Logarithmic FACS histograms showing the derivation of IgG_{2a} and IgG_{2b} variants of Genox 3:53. Traces are of cells stained with FITC-GAM1 (GAM1), FITC-GAM2 (GAM2), or not stained (NS). (A) The original IgG_1 secreting population of Genox 3.53 cells; (B) the population sorted from the whole population stained with FITC-GAM2; (C), (D) cells that grew out from first sorted population just before the second sort; (E) the population sorted at the second sort compared to the whole population stained with FITC-GAM2; (F) cells that grew out from the second sorted population just before cloning; (G) cloned IgG_{2b} variant 3.532b; and (H) cloned IgG_{2a} variants 3.532a.



with FITC-GAM2 revealed a small subpopulation of cells with a level of fluorescence similar to that of IgG₂ producing cells stained with FITC-GAM2. As listed in Table 2, 0.15% of the original Genox 3.53 population stained to a level to be included in the sort window shown in Figure 2(B). No cells were detected with this level of fluorescence in the unstained population of cells.

1.6×10^7 Genox 3.53 cells were stained with FITC-GAM2. Cells having fluorescence significantly above background were sorted into a single well of a 24 well culture plate. These cells were allowed to grow for one week and were then reanalyzed [Figs. 2(C),(D)]. As seen in Table 2 only a small fraction (0.26%) of the previously sorted cells stained specifically with FITC-GAM2. However, this subpopulation was enriched compared to the 0.15% found in the parent population. 6.4×10^6 cells were sorted for the second time [Fig. 2(E)] and 1539 cells (0.23% of total) collected in a single well of a 24 well plate. After several days of growth the cells were reanalyzed and at this stage: 52% of the cells stained specifically with FITC-GAM2 [Fig. 2(F)]. Individual, positively stained cells from this subpopulation were directly cloned with the FACS into individual wells of a 96 well culture plate [18].

Two weeks after cloning large colonies were seen in 35% of the wells. Supernatants from 48 colonies were assayed for indirect trace binding with ¹²⁵I-RAM against LB (DR6, DC1 positive) and Mich (DR5, DC1 negative) cells. Forty-seven gave strong binding to LB and no binding to Mich indicating they were still secreting antibodies with the original specificity. Supernatants from 28 of the active clones were then assayed on LB cells with ¹²⁵I-GAM1 and ¹²⁵I-GAM2. All bound 20–60,000 cpm ¹²⁵I-GAM2, and with one exception bound only 200–700 cpm of ¹²⁵I-GAM1. To distinguish between clones secreting IgG_{2a} and IgG_{2b} the assay was repeated using two monoclonal antibodies that recognize allotypic determinants of mouse immunoglobulin as the iodinated second step reagent. 16.3 reacts with both IgG_{2a} and IgG_{2b}, 8.3 only reacts with IgG_{2a} of C3H mice from which Genox 3.53 was derived [16]. In total, nine clones secreting IgG_{2a} and 56 secreting IgG_{2b} were identified. Six clones of each type were expanded and stocks of frozen cells made. One clone of each type was selected on the basis of growth and antibody production for further study. These were designated G2a.5 for one that secretes IgG_{2a} and G2b.2 for one that secretes IgG_{2b}. The variant cells secrete similar amounts of IgG as the parent hybridoma and can be similarly passaged as tumors in (BALB/c × C3H) F1 or irradiated BALB/c mice to give high titred ascites fluids [19]. These cells have been sent to the American Type Culture Collection hybridoma cell bank. (For information write to Dr. Anne Hamburger, Cell Culture Department, American Type Culture Collection, 12301 Park Lawn Drive, Rockville, MD 20852.)

TABLE 2 Isolation of IgG₂ switch variants of Genox 3.53

Population	Percent Number of cells in sort window	Number of cells selected	Total number of cells sorted	Percent selected
Parent	0.15	8.6×10^3	1.6×10^7	0.054
1st sorted culture	0.26	1.5×10^3	6.4×10^6	0.23
2nd sorted culture	52.0			

Cytotoxic Reactions of G2a and G2b

Supernatants were prepared by allowing hybridoma cells to overgrow and eventually die for seven days after they had reached optimal maximum density ($5-10 \times 10^5$ cells/ml). Cells and cellular debris were removed by centrifugation and 0.02% sodium azide added to the supernatants which were transported from Stanford University to Duke University at ambient temperature.

Hybridoma supernatants were tested for complement mediated cytotoxicity [20] on separated B and T lymphocytes [21] from 19 individuals well characterized for HLA antigens. Supernatants from the 12 IgG₂ secreting clones of Genox 3.53 were tested at three dilutions (neat, 1/2, 1/10). Control supernatants were from the parent IgG₁ secreting Genox 3.53; CA2.206, a monomorphic anti-DR (IgG_{2a}) [22]; BB7.2, anti-HLA-A2 (IgG_{2b}) [23]; BBM.1, anti- β_2 -m (IgG_{2b}) [24]; W6/32 (IgG_{2a}) [25]; and BB7.7 (IgG_{2b}) [19] monomorphic anti-HLA-A,B,C. The results are shown in Table 3. The Genox 3.53 IgG₁ was not cytotoxic to any cells. In contrast all the IgG₂ switch variants killed cells with the same specificity that the IgG₁ has by binding assay. Only B lymphocytes of DC1 positive individuals were killed by the IgG₂ variants of Genox 3.53. Complete cytotoxicity was seen at all dilutions tested and no differences were found between IgG_{2a} and IgG_{2b}. The control supernatant also killed cells according to their specificity as determined by binding assay [19,22-25]. As expected BBM1, BB7.7, and W6/32 killed all cells from all individuals. BB7.2 killed B and T lymphocytes from HLA-A2 positive individuals and CA2.206 killed B cells but not T cells from all individuals.

These results show that spontaneous isotype switching in hybridoma cells can be used to advantage in converting noncytotoxic anti-HLA monoclonal antibodies of useful specificity into cytotoxic reagents. It is not clear if antigen density will affect the cytotoxicity of monoclonal antibodies. However, as this method worked for DC1, an HLA antigen with relatively low levels of expression, it seems likely to be applicable to all anti-HLA. The availability of pairs of antibody of identical specificity, one that is cytotoxic and one that is not, will also provide useful tools for in vivo and in vitro studies of MHC antigens.

ACKNOWLEDGMENTS

This research was supported by NIH 1R01 grants A1 17892 (PP), GM 10356 (FEW), GM 17367, and A1 08917 (LAH) from the U.S. Public Health Services. TJK was supported by fellowship 1HLE616 from the National Leukaemia Association. We thank Kimberly Tadlock for technical assistance and Barbara Buckley for preparing the manuscript.

REFERENCES

1. Fuller TC, Phelan D, Gebel HM, Rodey GE: Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. *Transplantation* 34:24, 1982.
2. Krakauer H, Hartzman RJ, Johnson AH: Monoclonal antibodies specific for human polymorphic cell surface antigens I. Evaluation of Methodologies. Report on a Workshop. *Human Immunol* 4:167, 1982.
3. Radbruch A, Liesegang B, Rajewsky K: Isolation of variants of mouse myeloma X63 that express changed immunoglobulin class. *Proc Natl Acad Sci (USA)* 77:2909, 1980.
4. Dangl JL, Herzenberg LA: Selection of hybridomas and hybridoma variants using the fluorescence activated cell sorter. *J Immunol Meth* 52:1, 1982.

5. Dangl JL, Parks DR, Oi VT, Herzenberg LA: Rapid isolation of cloned isotype switch variants using fluorescence activated cell sorting. *Cytometry* 2:395, 1982.
6. Brodsky FM, Parham P, Bodmer WF: Monoclonal antibodies to HLA-DRw determinants. *Tissue Antigens* 16:30, 1979.
7. Shackelford DA, Mann DL, van Rood JJ, Ferrara GB, Strominger JL: Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct from the HLA-DR antigen. *Proc Natl Acad Sci (USA)* 78:4566, 1981.
8. Bono MR, Strominger JL: Direct evidence of homology between DC-1 antigen and murine I-A molecules. *Nature* 299:836, 1982.
9. March SC, Parikh I, Cuatrecasas P: A simplified method for cyanogen bromide activation of agarose for affinity chromatography. *Anal Biochem* 60:149, 1974.
10. Read RSD, Cox JC, Ward HA, Nairn JC: 1974. Conditions for purification of anti-Brucella antibodies by immunoadsorption and elution. *Immunochemistry* 11:819, 1974.
11. Goding JW: Conjugation of antibodies with fluorochromes: Modification to the standard methods. *J Immunol Meth* 13:215, 1976.
12. Goldman M: Labeling agents and procedures of conjugations. In: M. Goldman, Ed. *Fluorescence Antibody Methods*. New York, Academic Press, 1968, pp. 124–126.
13. McMaster WR, Winearls BC, Parham P: A monoclonal mouse anti-rat Ia antibody which cross-reacts with a human HLA-DRw determinant. *Tissue Antigens* 14:453, 1979.
14. Corte G, Calabi F, Damiani G, Bargellesi A, Tosi R, Sorrentino R: Human Ia molecules carrying DC1 determinants differ in both α - and β -subunits from Ia molecules carrying DR determinants. *Nature* 292:357, 1981.
15. Parham P, Androlewicz MJ, Brodsky FM, Holmes NJ, Ways JP: 1982. Monoclonal antibodies: Purification, fragmentation and application to structural and functional studies of class I MHC antigens. *J Immunol Meth* 53:133, 1982.
16. Huang CM, Parsons M, Wakeland EK, Moriwaki K, Herzenberg LA: New immunoglobulin IgG allotypes and haplotypes found in wild mice with monoclonal anti-allotope antibodies. *J Immunol* 128:661, 1982.
17. Mishell BB, Shiigi SM, Eds: *Selected Methods in Cellular Immunology*. San Francisco, W.H. Freeman and Co., 1980, pp. 8–9.
18. Parks DR, Bryan VM, Oi VT, Herzenberg LA: Antigen specific identification and cloning of hybridomas with a fluorescence-activated cell sorter (FACS). *Proc Natl Acad Sci (USA)* 76:1962, 1979.
19. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF: Monoclonal antibodies for analysis of the HLA system. *Immunol Rev* 47:3, 1979.
20. Amos DB, Bashier H, Boyle W, MacQueen M, Tiilikainen A: A simple microcytotoxicity test. *Transplantation* 7:220, 1969.
21. Johnson AH, Amos DB, Grier JO, Ward FE: Enrichment of B lymphocytes using an anti-F(ab')₂ monolayer. In: P.I. Terasaki, Ed. *Histocompatibility testing 1980*. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1980, pp. 285–286.
22. Charron DJ, McDevitt HO: Analysis of HLA-D region-associated molecules with monoclonal antibody. *Proc Natl Acad Sci (USA)* 76:6567, 1979.
23. Parham P, Brodsky FM: Partial purification and some properties of BB7.2: A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. *Human Immunol* 3:277, 1981.

24. Brodsky FM, Bodmer WF, Parham P: Characterization of a monoclonal anti- β_2 -microglobulin and its use in the genetic and biochemical analysis of major histocompatibility antigens. *Eur J Immunol* 9:536, 1979.
25. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A: Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens—new tools for genetic analysis. *Cell* 14:9, 1978.